←
Bram De Laere346 posts
Bram De Laere avatar

Bram De Laere

@BramDL

Biochemical engineer, PhD medical science @karolinskainst and @ugent, #ProstateCancer, #LiquidBiopsy & @ProBioTrial researcher. Views are my own

◷ Joined November 2016▧ 31 Photos and videos
Bram De Laere avatar
Bram De Laere@BramDL·20 Aug 2024

Privileged seeing the @ProBioTrial published in @NatureMedicine My sincerest gratitude for all the dedicated doctors, nurses, lab personnel, trial managers, and most importantly, the patients who made this possible🙏 Thank you @komop_tgkanker for making ProBio possible in🇧🇪

🔥📢 The first results from the @ProBioTrial have been published in @NatureMedicine 🚀🌟 ARPIs outperform taxanes in metastatic #ProstateCancer: an outcome-adaptive randomized platform trial 🌟 nature.com/articles/s41591-0… [1/10]

Piet Ost avatar
⟳ Bram De Laere retweeted
Piet Ost@piet_ost·Sep 7

Accrual is fast, now with Finland and Denmark added, it will go even faster! If pharma is interested, @ProBioTrial is looking for new molecules to be tested!

Post attachment
Piet Ost avatar
⟳ Bram De Laere retweeted
Piet Ost@piet_ost·Sep 7

What did @ProBioTrial prove in mCRPC? What can you do with the info of a liquid biopsy? From a concept starting in 2019 to practice informing data from PFS, OS and QoL (out soon) data.

Post attachment
ProBio avatar
⟳ Bram De Laere retweeted
ProBio@ProBioTrial·May 20

💡However, comparative randomised evidence is available from the ProBio trial (NCT03903835) in men with ARPI-naïve mCRPC and detectable ctDNA. Compared to taxanes, ARPIs were associated with: ✅ Longer time of clinical benefit (PCWG3) ✅ Longer overall survival ✅ Fewer (S)AE

Post attachment
ProBio avatar
⟳ Bram De Laere retweeted
ProBio@ProBioTrial·May 20

📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.

Post attachment
Michael Saerens avatar
⟳ Bram De Laere retweeted
Michael Saerens@msaerens01·Mar 30

The workflow of #ProBio trial is mindblowing: 14 day TAT to get a ctDNA 🩸🧬genomic profile and personalised treatment option in >5 🇪🇺 countries. Focus shifts to mHSPC setting. @crighent Priomic Symposium @piet_ost @BramDL

Post attachmentPost attachmentPost attachment
Bram De Laere avatar
Bram De Laere@BramDL·14 Jul 2025

📉 CDKN1A mutations weren’t tied to NAC response but were linked to worse survival outcomes — hinting at prognostic value regardless of molecular subtype. #Biomarkers 4/5

Post attachment
Bram De Laere avatar
Bram De Laere@BramDL·14 Jul 2025

Conversely, FGFR3 mutations were associated with poor response and inferior recurrence-free and overall survival — adding weight to growing evidence these patients may benefit from alternatives to NAC. ⚠️ #BladderCancer #FGFR3 3/5

Post attachment
Bram De Laere avatar
Bram De Laere@BramDL·14 Jul 2025

Using a targeted sequencing approach on 110 MIBC patients, we found focal amplifications on chr6p22.3 — particularly E2F3 and SOX4 — were linked to pathologic response and no recurrences after 5 years. 📈 #Genomics #UroOncology 2/5

Post attachment
Piet Ost avatar
⟳ Bram De Laere retweeted
Piet Ost@piet_ost·17 May 2025

But if you ask the companies @Merck to provide drug for a biomarker selection trial like @ProBioTrial, they refuse. Even if you ask for compassionate use for PCa MSI high in the trial!!! @BramDL

Piet Ost avatar
⟳ Bram De Laere retweeted
Piet Ost@piet_ost·5 May 2025

📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

Post attachmentPost attachment
Bram De Laere avatar
Bram De Laere@BramDL·22 Apr 2025

Proud to share the latest insights from the @ProBioTrial Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant #ProstateCancer 🩸🧬 Full text available on @EurUrolOncol : authors.elsevier.com/sd/arti…

🚨 New Study Alert! 🚨 What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC A thread 🧵👇 #CancerResearch #ProstateCancer [1/8]

Post attachment